Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Cross-bridge Cycle01:26

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HSD10 disease in a female: A case report and review of literature.

JIMD reports·2021
Same author

Further delineation of DDX3X syndrome.

Clinical dysmorphology·2019
Same author

Serial electrophysiologic studies in rhesus monkeys with Krabbe disease.

Muscle & nerve·2005
See all related articles

Related Experiment Videos

Lambert-eaton myasthenic syndrome.

Maria B Weimer1, Joaquin Wong

  • 1Maria B. Weimer, MD Louisiana State University Health Sciences Center, Department of Neurology, 200 Henry Clay Suite 3314, New Orleans, LA 70118, USA. mweime@lsuhsc.edu.

Current Treatment Options in Neurology
|February 13, 2009
PubMed
Summary

Lambert Eaton myasthenic syndrome (LEMS) is a rare neuromuscular disorder often misdiagnosed as myasthenia gravis. Early diagnosis and malignancy screening are crucial, with 3,4-diaminopyridine often improving strength.

Related Experiment Videos

Area of Science:

  • Neurology
  • Immunology

Background:

  • Lambert Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder affecting the neuromuscular junction.
  • LEMS symptoms are frequently misdiagnosed as myasthenia gravis, leading to delayed or incorrect diagnostic workups.

Purpose of the Study:

  • To highlight the diagnostic challenges and critical management strategies for Lambert Eaton myasthenic syndrome.
  • To emphasize the importance of investigating occult malignancies in LEMS patients.

Main Methods:

  • Review of diagnostic criteria for LEMS.
  • Discussion of electrophysiologic studies and serum calcium channel antibody testing.
  • Overview of therapeutic approaches including 3,4-diaminopyridine and immunosuppressants.

Main Results:

  • LEMS diagnosis can be confirmed via electrophysiologic studies or serum calcium channel antibodies.
  • 3,4-diaminopyridine is effective in improving muscle strength in most LEMS patients.
  • Malignancy screening is essential at diagnosis and for at least five years post-diagnosis.

Conclusions:

  • Accurate diagnosis of LEMS requires distinguishing it from myasthenia gravis.
  • Prompt identification and management of associated malignancies are paramount.
  • Awareness of potential exacerbating factors is crucial for patient and physician management.